Relay Therapeutics, Inc. (RLAY) annual balance sheet — 8-year assets, liabilities & equity history
| Total Current Assets | 658.46M | 578.28M | 809.2M | 770.1M | 1.02B | 976.24M | 770.1M | 360.54M | 424.1M |
| Cash & Short-Term Investments | 204.59M | 554.52M | 781.32M | 750.09M | 998.92M | 958.07M | 678.06M | 355.82M | 421.5M |
| Cash Only | 204.59M | 84.02M | 124.29M | 143.74M | 998.92M | 280.12M | 447.65M | 41.95M | 421.5M |
| Short-Term Investments | 0 | 470.5M | 657.04M | 606.35M | 0 | 677.95M | 230.41M | 313.86M | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 5.22M | 4.94M | 82.65M | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | 1.38K | 595.28 | 365 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 12.11M | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 453.87M | 23.76M | 10.53M | 3.31M | 3.26M | 1.76M | 0 | 0 | 0 |
| Total Non-Current Assets | 41.15M | 43.05M | 62.09M | 73.88M | 80.27M | 32.2M | 29.73M | 32.53M | 4.51M |
| Property, Plant & Equipment | 39.81M | 41.72M | 57.67M | 68.87M | 75.39M | 27.32M | 28.83M | 31.65M | 3.63M |
| Fixed Asset Turnover | 0.25x | 0.37x | 0.17x | 0.37x | 0.02x | 0.11x | 2.87x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 2.3M | 2.3M | 2.3M | 2.3M | 0 | 0 | 0 |
| Long-Term Investments | 1.34M | 1.34M | 0 | 2.71M | 2.58M | 0 | 0 | 0 | 878K |
| Other Non-Current Assets | 1.34M | 0 | 2.12M | 0 | 2.58M | 2.58M | 900K | 878K | 0 |
| Total Assets | 699.61M | 621.33M | 871.3M | 843.98M | 1.1B | 1.01B | 799.83M | 393.07M | 428.61M |
| Asset Turnover | 0.02x | 0.02x | 0.01x | 0.03x | 0.00x | 0.00x | 0.10x | - | - |
| Asset Growth % | -74.79% | -28.69% | 3.24% | -23.26% | 9.06% | 26.08% | 103.48% | -8.29% | - |
| Total Current Liabilities | 29.75M | 25.58M | 50.73M | 30.27M | 63.71M | 24.32M | 13.63M | 11.99M | 6.87M |
| Accounts Payable | 4.1M | 7.71M | 14.1M | 9.21M | 10.58M | 8.28M | 6.35M | 6.99M | 4.71M |
| Days Payables Outstanding | 3.01K | 790.65 | - | - | - | - | 653.17 | 896.91 | 797.27 |
| Short-Term Debt | 3.89M | 3.77M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 7.68M | 0 | 0 | 248K | 0 | 0 | 1.86M |
| Other Current Liabilities | 21.76M | 14.11M | 2.1M | 1.91M | 26.15M | 989K | 197K | 333K | 118K |
| Current Ratio | 22.13x | 22.61x | 15.95x | 25.44x | 16.00x | 40.14x | 56.49x | 30.08x | 61.78x |
| Quick Ratio | 22.13x | 22.61x | 15.95x | 25.44x | 15.81x | 40.14x | 56.49x | 30.08x | 61.78x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 27.68M | 28.69M | 42.77M | 61.71M | 85.84M | 86.31M | 22.9M | 561.52M | 532.67M |
| Long-Term Debt | 27.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 89.04M | 28.69M | 42.77M | 48.5M | 53.47M | 21.06M | 22.9M | 23.58M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 13.21M | 32.38M | 65.26M | 3K | 537.94M | 532.67M |
| Total Liabilities | 57.43M | 54.27M | 93.5M | 91.98M | 149.55M | 110.64M | 36.54M | 573.51M | 539.54M |
| Total Debt | 31.57M | 32.46M | 48.5M | 53.47M | 57.74M | 22.9M | 24.42M | 24.83M | 178K |
| Net Debt | -173.02M | -51.56M | -75.78M | -90.27M | -941.17M | -257.22M | -423.22M | -17.12M | -421.33M |
| Debt / Equity | 0.05x | 0.06x | 0.06x | 0.07x | 0.06x | 0.03x | 0.03x | - | - |
| Debt / EBITDA | -0.11x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.58x | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | 642.18M | 567.06M | 777.79M | 752M | 950.22M | 897.81M | 763.29M | -180.44M | -110.93M |
| Equity Growth % | -67.95% | -27.09% | 3.43% | -20.86% | 5.84% | 17.62% | 523.02% | -62.66% | - |
| Book Value per Share | 3.57 | 3.30 | 5.44 | 6.13 | 8.47 | 9.44 | 8.46 | -42.15 | -44.64 |
| Total Shareholders' Equity | 642.18M | 567.06M | 777.79M | 752M | 950.22M | 897.81M | 763.29M | -180.44M | -110.93M |
| Common Stock | 182K | 168K | 168K | 127K | 121K | 109K | 90K | 4K | 3K |
| Retained Earnings | -2.09B | -2.01B | -1.74B | -1.4B | -1.06B | -768.1M | -404.23M | -189.48M | -114.18M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -172K | 733K | -991K | -196K | -10.42M | -1.09M | 64K | 325K | -4.65M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying RLAY stock.
As of 2025, Relay Therapeutics, Inc. (RLAY) had total assets of $621.3M including $578.3M in current assets.
Relay Therapeutics, Inc. (RLAY) carries total debt of $32.5M, offset by $554.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Relay Therapeutics, Inc. (RLAY) has total shareholders' equity (book value) of $567.1M ($3.30 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Relay Therapeutics, Inc. (RLAY) reported a current ratio of 22.61x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.